Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLARINEX-D 12 HOUR vs ACUVUE THERAVISION WITH KETOTIFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Relief of symptoms associated with seasonal allergic rhinitis,Relief of symptoms associated with perennial allergic rhinitis,Relief of nasal congestion and sinus pressure
FDA-approved for the prevention and treatment of ocular itching associated with allergic conjunctivitis
1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
Desloratadine: 27 hours (terminal), allows once-daily dosing; pseudoephedrine: 4-6 hours (prolonged in alkaline urine).
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Desloratadine: primarily metabolized by CYP3A4 and CYP2D6 to active metabolite 3-hydroxydesloratadine. Pseudoephedrine: partially metabolized in liver by N-demethylation via CYP450 enzymes; largely excreted unchanged in urine.
Not significantly metabolized in the eye; systemic absorption is minimal. After systemic absorption, it is metabolized primarily via glucuronidation and oxidation, with a half-life of approximately 12 hours.
Desloratadine: 40.2% renal (unchanged and metabolites), 41.7% fecal; pseudoephedrine: 70-90% renal (unchanged).
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Desloratadine: 83-87% (mainly albumin); pseudoephedrine: negligible binding.
99% (primarily albumin and alpha-1-acid glycoprotein).
Desloratadine: 49 L (approx. 0.7 L/kg), extensive tissue distribution; pseudoephedrine: 2.6-3.5 L/kg.
2.4 L/kg (high tissue distribution, including ocular tissues).
Desloratadine: 100% (oral); pseudoephedrine: ~100% (oral).
Ocular topical: ~0.1% systemic; oral: 70% (not relevant for contact lens application).
Contraindicated in patients with GFR < 60 m L/min due to pseudoephedrine component.
No dosage adjustment required based on renal function; systemic absorption is minimal.
No specific Child-Pugh based adjustments for desloratadine; pseudoephedrine may require caution in severe hepatic impairment.
No dosage adjustment required based on hepatic function; systemic absorption is minimal.
Not recommended for use in pediatric patients under 12 years of age.
Safety and efficacy in pediatric patients below 3 years of age have not been established. For children 3 years and older, administer one drop in each affected eye twice daily.
Use with caution; initiate at lower doses due to increased sensitivity to pseudoephedrine and risk of anticholinergic effects.
No specific dosage adjustment is required for elderly patients; use same dosing as for adults.
None.
None
Cardiovascular effects: Use with caution in patients with hypertension, arrhythmias, or ischemic heart disease.,CNS stimulation: May cause insomnia, dizziness, or nervousness.,Urinary retention: Use with caution in patients with prostatic hypertrophy or bladder neck obstruction.,Renal impairment: Reduce dose or avoid in severe renal impairment.,Hepatic impairment: Caution in severe hepatic disease.
For topical ophthalmic use only; not for injection.,Contains benzalkonium chloride; soft contact lens wearers should remove lenses before application and wait at least 10 minutes before reinserting.,May cause transient stinging or burning upon instillation.,Use with caution in patients with known hypersensitivity to any component.
Hypersensitivity to desloratadine, pseudoephedrine, or any component,Severe hypertension or coronary artery disease,Concurrent use with MAO inhibitors or within 14 days of stopping MAOI,Narrow-angle glaucoma,Urinary retention,Breastfeeding
Hypersensitivity to ketotifen or any component of the product.
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented foods) as pseudoephedrine may potentiate pressor effects. Taking with food may reduce gastrointestinal irritation. Avoid grapefruit juice; it may increase desloratadine levels. Limit caffeine intake as it can add to CNS stimulation.
None reported.
Clarinox-D 12 Hour (desloratadine/pseudoephedrine) is classified as FDA Pregnancy Category C. Desloratadine: No adequate studies in pregnant women; animal studies show no teratogenicity at doses 210 times human exposure, but potential for adverse effects is unknown. Pseudoephedrine: Case reports suggest possible association with gastroschisis at first-trimester exposure; vasoconstriction may reduce uteroplacental blood flow, especially in third trimester. Avoid in first trimester if possible; use only if benefit outweighs risk.
Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenicity at doses up to 50 mg/kg/day orally. Risk to fetus is considered low when used topically as directed.
Desloratadine: Excreted into breast milk; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. Pseudoephedrine: Excreted into breast milk; estimated infant dose ~2-7% of maternal dose; may cause irritability, sleep disturbance. M/P ratio: not reported for desloratadine; pseudoephedrine M/P ~3.0. Manufacturer recommends caution due to pseudoephedrine's effects.
Ketotifen is excreted in human milk following oral administration; however, systemic absorption from ophthalmic use is negligible. M/P ratio not established for ophthalmic route. Consider benefit vs risk; caution in breastfeeding mothers.
No specific dose adjustments required for desloratadine; pregnancy may increase volume of distribution but no clinical studies. Pseudoephedrine: Pregnancy may reduce clearance; no formal dose adjustment but use lowest effective dose and shortest duration. Monitor for hypertension.
No dosage adjustment required. Use as directed; pharmacokinetic changes in pregnancy are not significant for topical ophthalmic route.
CLARINEX-D 12 HOUR (desloratadine/pseudoephedrine) combines a non-sedating antihistamine with a sympathomimetic decongestant. Pseudoephedrine can cause hypertension, tachycardia, and urinary retention; avoid in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Desloratadine is the active metabolite of loratadine; it is less sedating than first-generation antihistamines. The 12-hour formulation requires twice-daily dosing. Monitor for CNS stimulation and insomnia, especially in elderly or pediatric patients.
Ketotifen is a mast cell stabilizer and antihistamine; contact lens must be removed before instillation and may be reinserted after 10 minutes. Do not use while wearing contact lenses. Advise patient to wait at least 5 minutes between different eye drops. The preservative benzalkonium chloride may be absorbed by soft contact lenses.
Take one tablet every 12 hours with a full glass of water; do not crush or chew.,Do not exceed 2 tablets in 24 hours.,Avoid alcohol and other CNS depressants while taking this medication.,May cause dizziness or drowsiness; avoid driving until you know how the medication affects you.,Notify your doctor if you have high blood pressure, heart disease, thyroid problems, or difficulty urinating.,Discontinue use and seek medical attention if you experience chest pain, rapid heartbeat, or difficulty breathing.,Do not take with other decongestants or antihistamines without consulting a healthcare provider.
Remove contact lenses before using the drops and wait at least 10 minutes before reinserting.,Wash hands before use. Do not touch the dropper tip to any surface, including the eye.,Do not use if the solution changes color or becomes cloudy.,Use exactly as prescribed; do not use more often than directed.,If you miss a dose, use it as soon as possible. If it is almost time for the next dose, skip the missed dose and resume your regular schedule. Do not double the dose.,Contact your doctor if you experience eye pain, vision changes, or if symptoms persist or worsen.
No interactions on record
"Lisdexamfetamine, a prodrug of dextroamphetamine, increases central nervous system (CNS) arousal via dopamine and norepinephrine release, counteracting the sedative effects of ketotifen, a mast cell stabilizer with histamine H1-receptor antagonism and CNS depressant properties. The interaction results in reduced sedative efficacy of ketotifen, potentially affecting therapeutic outcomes in allergic conditions where sedation is beneficial, such as severe pruritus or urticaria. Clinically, patients may experience decreased drowsiness or sleepiness, which could be undesirable if ketotifen is prescribed specifically for its soporific effects."
"Pseudoephedrine, a sympathomimetic amine, exerts central nervous system (CNS) stimulant effects by indirectly activating adrenergic receptors, which can counteract the sedative properties of ketotifen, a histamine H1-receptor antagonist with mast cell stabilizing activity. This pharmacodynamic antagonism may reduce the therapeutic efficacy of ketotifen in managing allergic conditions, particularly its ability to cause drowsiness as a side effect. Clinically, patients may experience diminished sedation, potentially leading to decreased compliance or altered therapeutic outcomes in conditions where sedation is beneficial."
"Hydroxyamphetamine, an indirect-acting sympathomimetic amine, stimulates the release of norepinephrine from presynaptic nerve terminals, leading to activation of alpha- and beta-adrenergic receptors. This produces central nervous system (CNS) stimulation that may oppose the sedative effects of ketotifen, a histamine H1-receptor antagonist with sedative properties. Consequently, coadministration may result in reduced efficacy of ketotifen for sedation or sleep induction, potentially compromising its therapeutic benefit in conditions requiring CNS depression (e.g., allergic rhinitis, urticaria)."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLARINEX-D 12 HOUR vs ACUVUE THERAVISION WITH KETOTIFEN, answered by our medical review team.
CLARINEX-D 12 HOUR is a Antihistamine/Decongestant Combination that works by Desloratadine is a long-acting tricyclic histamine antagonist selective for H1-receptor with additional anti-inflammatory properties. Pseudoephedrine is a sympathomimetic amine that acts as a vasoconstrictor via alpha-adrenergic receptors.. ACUVUE THERAVISION WITH KETOTIFEN is a Antihistamine / Mast Cell Stabilizer that works by Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLARINEX-D 12 HOUR and ACUVUE THERAVISION WITH KETOTIFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLARINEX-D 12 HOUR is: 1 tablet (5 mg desloratadine / 120 mg pseudoephedrine) orally every 12 hours.. The standard adult dose of ACUVUE THERAVISION WITH KETOTIFEN is: One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLARINEX-D 12 HOUR and ACUVUE THERAVISION WITH KETOTIFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLARINEX-D 12 HOUR is classified as Category C. Clarinox-D 12 Hour (desloratadine/pseudoephedrine) is classified as FDA Pregnancy Category C. Desloratadine: No adequate studies in pregnant women; animal studies show no teratogen. ACUVUE THERAVISION WITH KETOTIFEN is classified as Category A/B. Ketotifen ophthalmic solution has minimal systemic absorption (approximately 0.1% of administered dose). No adequate well-controlled studies in pregnant women. Animal studies showe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.